SpectrumX Holdings UK Ltd appointed a new microbiology team as part of its strategy to expand its R&D division and enhance product range development and commercialisation.
The team will consist of Annaliese Waite, who has been appointed head of microbiology, and microbiologist Heather Lloyd, the UK-based healthcare and pharmaceutical company said in a statement.
Waite, a Bachelor of Science (BSc), has extensive microbiology experience at large pharmaceutical companies, including AstraZeneca, where she developed rapid sterility testing for the Covid-19 vaccine, the company said.
Most recently, she was a member of the technical team at antimicrobial technologies company Byotrol (AIM:BYOT), where she focused on microbiological testing and conducting preparatory procedures to ensure quality standards.
Waite’s role at SpectrumX will involve using her industry expertise to expand the company’s product R&D capabilities through developing testing methods, managing its laboratories, and preparing a quality control programme for SpectrumX’s products.
This will allow the company to implement regulatory procedures in preparation for market authorisation.
Meanwhile, Lloyd (MSc, Licentiate of the Institute of Biomedical Science) is experienced in assessing antimicrobial efficacy of both industrial and cosmetic product samples. Her efficacy testing expertise will inform and enhance the development and production of SPX-001, SpectrumX’s prospective antipathogenic medicinal treatment that contains the company’s patent-pending formulation of hypochlorous acid (HOCl).
“We are pleased to have appointed Annaliese and Heather to expand our product R&D capabilities at SpectrumX,” commented CEO Damien Hancox.
“The wealth of knowledge and insight these talented individuals bring will support us on the path to commercialising our products. These appointments signal our intention to building out our product R&D team and illustrate our commitment to quickly and efficiently bring our products to market.”